Centogene, Evotec Expand Collaboration to Develop New Gaucher Treatments

Centogene and Evotec have expanded their collaboration agreement to focus on the development of new treatments for Gaucher disease and other rare disorders caused by mutations in the GBA gene, the companies announced. This expanded partnership builds upon a previous collaboration agreement, launched in 2018,…

Lysogene, Weizmann Institute Team Up on Gene Therapy for Neuronopathic Gaucher

Lysogene has entered into a collaborative research agreement with Yeda Research and Development, a commercial branch of the Weizmann Institute of Science, to develop a gene therapy for neuronopathic Gaucher disease that affects the brain and spinal cord, the biopharmaceutical company announced. The therapy also…